title: Diabetes abolishes the gender difference in vasopressin-mediated potentiation of sympathetic vasoconstriction.
abstract: Electrical field stimulation (4 Hz, 0.2 ms pulse duration, at a supramaximal voltage of 70 V, for 1 s) of isolated rat tail artery segments produced contraction which was lower in female than in male rats, and was reduced by streptozotocin-induced diabetes in both genders. This contraction was potentiated by vasopressin (10(-12)-10(-10) M) more in normoglycemic male than in normoglycemic female rats, and this effect of vasopressin was increased by the cyclooxigenase inhibitor meclofenamate (10(-5) M) in female control rats, but not in diabetic female, or control and diabetic male rats, and it was not modified by the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME, 10(-4) M). Endothelin-1 (10(-10)-3 x 10(-9) M) also potentiated the contraction to electrical stimulation. This potentiation was similar in all experimental groups, and it was not modified by meclofenamate or L-NAME. These results suggest that the potentiating effect of vasopressin, but not that of endothelin-1, on the sympathetic vasoconstriction, is lower in females than in males, probably by an increased release of vasodilating prostanoids, and this release may be reduced by diabetes in females.
authors.affiliation: Departamento de Fisiología, Facultad de Medicina, Universidad Autónoma, Arzobispo Morcillo 2, 28029 Madrid, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Sanz
authors.forename: L
authors.initials: L
authors.lastname: Monge
authors.forename: N
authors.initials: N
authors.lastname: Fernández
authors.forename: M A
authors.initials: MA
authors.lastname: Martínez
authors.forename: G
authors.initials: G
authors.lastname: Diéguez
authors.forename: A L
authors.initials: AL
authors.lastname: García-Villalón
mesh_terms: D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004558:Electric Stimulation; D019332:Endothelin-1 / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008469:Meclofenamic Acid / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D012737:Sex Factors; D013564:Sympathetic Nervous System / Q000502:physiology*; D013623:Tail / Q000098:blood supply; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D014667:Vasopressins / Q000494:pharmacology*
chemical_list: D016861:Cyclooxygenase Inhibitors; D019332:Endothelin-1; D004791:Enzyme Inhibitors; D014667:Vasopressins; D008469:Meclofenamic Acid; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester